Theratechnologies Reports Q2 2025 Financial Results and Acquisition Agreement

Theratechnologies ( (TSE:TH) ) has issued an announcement.

Theratechnologies reported a total revenue of $17.7 million for the second quarter of 2025, with a positive adjusted EBITDA for the fifth consecutive quarter. Despite a previous supply disruption affecting EGRIFTA SV® sales, the company has seen a strong demand recovery and record patient enrollments. The company is set to launch a new version of EGRIFTA WR™ in the third quarter, aiming to continue its growth trajectory. Additionally, Theratechnologies has entered into an agreement to be acquired by an affiliate of Future Pak, which has led to the withdrawal of its fiscal 2025 revenue and adjusted EBITDA guidance.

The most recent analyst rating on (TSE:TH) stock is a Buy with a C$3.80 price target. To see the full list of analyst forecasts on Theratechnologies stock, see the TSE:TH Stock Forecast page.

Spark’s Take on TSE:TH Stock

According to Spark, TipRanks’ AI Analyst, TSE:TH is a Neutral.

Theratechnologies’ overall stock score reflects significant strengths from recent corporate events and earnings call, which highlight growth potential and strategic improvements. However, these are tempered by ongoing financial challenges and valuation concerns, indicating a need for cautious optimism amidst potential risks.

To see Spark’s full report on TSE:TH stock, click here.

More about Theratechnologies

Theratechnologies Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies. The company is known for its products EGRIFTA SV® and Trogarzo®, which are primarily aimed at addressing unmet medical needs in the field of HIV treatment.

Average Trading Volume: 132,736

Technical Sentiment Signal: Hold

Current Market Cap: C$199.1M

See more insights into TH stock on TipRanks’ Stock Analysis page.